Literature DB >> 10655347

Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

C C Sanders1, M Peyret, E S Moland, C Shubert, K S Thomson, J M Boeufgras, W E Sanders.   

Abstract

The Advanced Expert System (AES) was used in conjunction with the VITEK 2 automated antimicrobial susceptibility test system to ascertain the beta-lactam phenotypes of 196 isolates of the family Enterobacteriaceae and the species Pseudomonas aeruginosa. These isolates represented a panel of strains that had been collected from laboratories worldwide and whose beta-lactam phenotypes had been characterized by biochemical and molecular techniques. The antimicrobial susceptibility of each isolate was determined with the VITEK 2 instrument, and the results were analyzed with the AES to ascertain the beta-lactam phenotype. The results were then compared to the beta-lactam resistance mechanism determined by biochemical and molecular techniques. Overall, the AES was able to ascertain a beta-lactam phenotype for 183 of the 196 (93.4%) isolates tested. For 111 of these 183 (60.7%) isolates, the correct beta-lactam phenotype was identified definitively in a single choice by the AES, while for an additional 46 isolates (25.1%), the AES identified the correct beta-lactam phenotype provisionally within two or more choices. For the remaining 26 isolates (14.2%), the beta-lactam phenotype identified by the AES was incorrect. However, for a number of these isolates, the error was due to remediable problems. These results suggest that the AES is capable of accurate identification of the beta-lactam phenotypes of gram-negative isolates and that certain modifications can improve its performance even further.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655347      PMCID: PMC86150     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.

Authors:  E Vercauteren; P Descheemaeker; M Ieven; C C Sanders; H Goossens
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

Review 2.  beta-Lactamases of gram-negative bacteria: new challenges for new drugs.

Authors:  C C Sanders
Journal:  Clin Infect Dis       Date:  1992-05       Impact factor: 9.079

Review 3.  Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.

Authors:  A A Medeiros
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

4.  Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins.

Authors:  C H O'Callaghan; P W Muggleton; G W Ross
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

Review 5.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

6.  Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

8.  Use of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens.

Authors:  K S Thomson; C C Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 9.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

10.  Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?

Authors:  E S Moland; C C Sanders; K S Thomson
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more
  20 in total

1.  BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Authors:  Christine C Sanders; Anton F Ehrhardt; Ellen Smith Moland; Kenneth S Thomson; Barbara Zimmer; Darcie E Roe
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

2.  Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital.

Authors:  C C Sanders; M Peyret; E S Moland; S J Cavalieri; C Shubert; K S Thomson; J M Boeufgras; W E Sanders
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

Review 3.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.

Authors:  Maurine A Leverstein-van Hall; Ad C Fluit; Armand Paauw; Adrienne T A Box; Sylvain Brisse; Jan Verhoef
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

6.  Utility of the VITEK 2 Advanced Expert System for identification of extended-spectrum beta-lactamase production in Enterobacter spp.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; Inna Chmelnitsky; Azita Leavitt; David Schwartz; Yehuda Carmeli
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

7.  Metallo-beta-lactamase or extended-spectrum beta-lactamase: a wolf in sheep's clothing.

Authors:  Björn A Espedido; Lee C Thomas; Jonathan R Iredell
Journal:  J Clin Microbiol       Date:  2007-04-04       Impact factor: 5.948

8.  Performance of Vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of beta-lactam resistance.

Authors:  Annarita Mazzariol; Marco Aldegheri; Marco Ligozzi; Giuliana Lo Cascio; Raffaella Koncan; Roberta Fontana
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

9.  Quality control for beta-lactam susceptibility testing with a well-defined collection of Enterobacteriaceae and Pseudomonas aeruginosa strains in Spain.

Authors:  Rafael Cantón; Elena Loza; María Del Carmen Conejo; Fernando Baquero; Luis Martínez-Martínez
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

10.  Rapid detection of methicillin resistance in coagulase-negative Staphylococci with the VITEK 2 system.

Authors:  Matthias A Horstkotte; Johannes K-M Knobloch; Holger Rohde; Sabine Dobinsky; Dietrich Mack
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.